key: cord-0335414-9vp1qbsr authors: Moore, Catherine M.; Wang, Jigang; Lin, Qingsong; Ferreira, Pedro; Avery, Mitchell A.; Elokely, Khaled; Staines, Henry M.; Krishna, Sanjeev title: Selective inhibition of PfATP6 by artemisinins and identification of new classes of inhibitors after expression in yeast date: 2021-10-28 journal: bioRxiv DOI: 10.1101/2021.10.27.466210 sha: 1db0a7c8a23c96e43f72511a5eea948b2866814f doc_id: 335414 cord_uid: 9vp1qbsr Treatment failures with artemisinin combination therapies (ACTs) threaten global efforts to eradicate malaria. They highlight the importance of identifying drug targets and new inhibitors and of studying how existing antimalarial classes work. Herein we report the successful development of an heterologous expression-based compound screening tool. Validated drug target P. falciparum calcium ATPase6 (PfATP6) and a mammalian ortholog (SERCA1a) were functionally expressed in yeast providing a robust, sensitive, and specific screening tool. Whole-cell and in vitro assays consistently demonstrated inhibition and labelling of PfATP6 by artemisinins. Mutations in PfATP6 resulted in fitness costs that were ameliorated in the presence of artemisinin derivatives when studied in the yeast model. As previously hypothesised, PfATP6 is a target of artemisinins. Mammalian SERCA1a can be mutated to become more susceptible to artemisinins. The inexpensive, low technology yeast screening platform has identified unrelated classes of druggable PfATP6 inhibitors. Resistance to artemisinins may depend on mechanisms that can concomitantly address multi-targeting by artemisinins and fitness costs of mutations that reduce artemisinin susceptibility. preventing it from binding ( Figure 2c ). The addition of haem increased labelling 158 of PfATP6 exposed to tagged dihydroartemisinin, as it does in parasites ( Figure 159 2b and 18 ). Conversely, chelation of Fe 3+ using desferrioxamine (DFO) 160 attenuates the interactions between artemisinins and targets ( Figure 2b) . 161 Immunofluorescence assays with parasites using a FITC-labelled anti-biotin 162 antibody localised the tagged dihydroartemisinin to the area surrounding the 163 nucleus, most likely the ER, which is where PfATP6 is localised (Figure 2d Hits from the compound screen are summarised in Figure 3a . Initially six hits 176 were identified from the MMV malaria box. Three of these hits gave results 177 that were too variable to take forward. MMV665807 showed the highest 178 reproducible potency against PfATP6 with almost no inhibition of control 179 strains (K667DPDR5::SERCA1a and K667DPDR5::pUGpd). Hits from the 180 malaria box were characterised in more detail (Table 3) After expression in Xenopus oocytes, sensitivity of SERCA1a to artemisinins 199 was increased by mutating a key amino acid residue (E255L) in the 200 thapsigargin-binding pocket 29,30 . We confirmed that E255L SERCA1a was more 201 sensitive to all tested artemisinins, and conversely became five-fold less 202 sensitive to thapsigargin i.e. IC50 = 793.6 ± 247.4 nM, versus 146.8 ± 43.9 nM 203 for wild-type (p = 0.011) (Figure 4a and These naturally occurring mutations were also supplemented by an L263E 212 mutation that we have previously shown to confer variable resistance in 213 parasites to artemisinins, as it substitutes the malarial amino acid for the 214 mammalian equivalent. Pulcini et al (Table 1 ; 13 ) also showed that these yeast expressing this mutant had a growth advantage, especially when starting 252 mixtures were in a ratio of 1:3 (native:mutant ratio; Figure 3d ). When CPA was 253 used (5 µM: approximately yeast IC80) instead of artemether as a selective 254 agent, S769N PfATP6 lost this advantage. 255 In silico modelling shows the changes in the druggable pockets with different 256 mutations ( Figure 5) . The X-ray crystal structure of the SERCA in E2 (E309A 257 mutant) was used as a template for building the homology models of PfATP6 258 and its mutations. Our early work also pointed to a family of P-type cation ATPases as promising 275 for further study as drug targets. PfATP4 was characterised as an atypical 276 cation ATPase initially proposed to be a calcium ATPase 39 and then was found 277 to export sodium from the intraerythrocytic parasite 40 To confirm that mammalian SERCA1a can be made more susceptible to 323 artemisinins, we also mutated its sequence as before ( E255L SERCA1a) and 324 again demonstrated increased susceptibility to artemisinins 29 (Fig 4a) 325 Interestingly, this sequence is less susceptible to thapsigargin (Fig 4b) . These 326 observations confirm that artemisinins target PfATP6, and that this inhibition 327 can result in increases in free intraparasitic calcium concentrations when 328 challenged with a potent artemisinin (Fig 3c) . These observations also highlight 329 how methodologies used to assay function in different expression systems may 330 give apparently inconsistent results. In vitro activity assays also demonstrate 331 this point, as no compound tested showed any inhibition of purified PfATP6 332 despite apparent inhibition of purified SERCA1a by CPA in parallel Treatment failure with artemisinin combination therapy (ACT) emerged in the 336 early 1990s and is currently localised to the Greater Mekong region 43,44 . 337 Fortunately, appropriately selected ACTs continue to be effective in treating P. 338 falciparum infections in this region when the partner drug is efficacious, and 339 case numbers continue to fall 45 . 340 Using PfATP6 as a 'model' target allowed assessment of the importance of 341 other targets, because even with mutations that are predicted to decrease 342 sensitivity of PfATP6, assays in parasites bearing such mutations suggested 343 more variable IC50 results, both in field and laboratory generated strains. 344 Fitness cost in the yeast model is ameliorated when these PfATP6 mutant 345 strains are exposed to artemisinin derivatives, perhaps explaining why some 346 parasites strains have been unstable in the laboratory when grown without drug 347 selection pressure 32 . Future fitness cost assays could be carried out with yeast 348 that have fluorescent markers incorporated into chromosomal DNA, rather than 349 in a vector, to provide a simpler 'plug-and-play' platform. 350 To address problems of drug resistance in parasites, we exploited the yeast 351 screening model, as it is eukaryotic, easily genetically manipulated, and knock-352 out libraries are freely available (e.g. through EUROSCARF, Germany). One 353 limitation is that any proposed target needs to have an orthologue in yeast, so 354 targeting mechanisms that relate to parasite-specific properties such as red cell 355 invasion might be difficult. Also, anti-parasitic drugs are often stage-specific 356 included in the yeast growth assays. Haem abolishes artemisinins' ability to inhibit yeast growth in fermentable media 46 . Also yeast has many efflux pumps 368 that lower its sensitivity to inhibitors, and K667DPDR5::HIS[PfATP6] yeast was 369 4-11 times more sensitive to artemisinins than the K667[PfATP6] strain. We did 370 not knock out other potential efflux pumps, of which more than a dozen remain. 371 This mechanism and its relevance to parasites is amenable to further study by 372 introduction, for example, of the P. falciparum efflux pump Pfmdr1. 373 In conclusion, several independent experimental findings are consistent with 374 the hypothesis that artemisinins target PfATP6. PfATP6 can be inhibited by a 375 variety of unrelated compounds after heterologous expression in a yeast 376 screening system, demonstrating its potential as a drug target, and potencies 377 Transformations 408 Yeast transformations were performed using the method described by Gietz 409 and Schiestl 47 and transformants were selected by an uracil auxotrophic To knock out the PDR5 gene from the K667 strain of yeast, the auxotrophic 423 marker HISMX was amplified using the following primers 20 : 424 where the underlined region is homologous with HISMX. PCR products were 427 used to transform the K667 strain as above. Knockouts were selected by their 428 ability to grow on histidine-depleted selective medium. Recombination was 429 confirmed with colony PCR. Red-tagged) was added and incubated for at least two hours. The slides were 439 stained with 5 μM Di6OC for 20 minutes to stain endoplasmic reticulum. 440 Antifade mounting medium plus DAPI was added before sealing the slides. 441 Yeast were visualised with a Zeiss Confocal LSM 510 microscope. Activity assays were performed as in Longland et al. 54 and LeBel et al. 55 , except 567 the reactions were incubated at 30°C instead of 37°C. Briefly, microsomes were 568 diluted to 75 µg/ml, with free calcium at approximately 1 µM, in 2 ml assay buffer 569 (45 mM HEPES/KOH pH 7.2, 6 mM MgCl2, 2 mM NaN3, 250 mM sucrose, 12.5 570 µg/ml A23187, 2 mM EGTA, ± 2mM CaCl2) and incubated for 10 minutes at 571 30°C in presence/absence of inhibitor (10-100 µM). Then 5.8 mM ATP was 572 added and incubated for a further 15 minutes at 30°C. The reaction is stopped 573 with 0.5 ml 6.5% TCA, on ice, and centrifuged at 4°C for 10 minutes (16,000 574 xg). 0.5 ml of the supernatant was added to 1.5 ml of copper acetate buffer 575 (0.25% copper sulphate pentahydrate, 4.6% sodium acetate trihydrate, 576 dissolved in 2M acetic acid pH 4.0) and mixed by vortexing, before addition of 577 0.25 ml of 5% ammonium molybdate, followed by 0.25 ml METOL buffer (2% 578 p-methyl-aminophenol sulphate, 5% sodium sulphite). Samples were incubated 579 for 10 minutes and absorbance measured at 870 nm in spectrophotometer. Pi Artemisinins as a novel anti-623 cancer therapy: Targeting a global cancer pandemic through drug 624 repurposing Artemisinins target the SERCA of Plasmodium falciparum Design, synthesis, and development of novel guaianolide-630 endoperoxides as potential antimalarial agents Investigations into the role of the Plasmodium falciparum SERCA (PfATP6) L263E mutation in artemisinin action and resistance Reflections on PfATP6 as the target for artemisinins Expression in Yeast Links Field Polymorphisms in PfATP6 to in Vitro Artemisinin Resistance and Identifies New Inhibitor Mammalian Sarcoendoplasmic Reticulum Calcium Adenosine 645 Haem-activated promiscuous targeting of artemisinin in 658 Plasmodium falciparum Artemisinin activity-based probes identify multiple Yeast-based automated high-throughput screens to 664 identify anti-parasitic lead compounds Mechanistic Investigation of the Specific Anticancer 666 Property of Artemisinin and Its Combination with Aminolevulinic Acid for The Open Access Malaria Box: A Drug 670 Discovery Catalyst for Neglected Diseases A Simple Statistical 673 Parameter for Use in Evaluation and Validation of High Throughput 674 Screening Assays Ca2+ monitoring in Plasmodium falciparum using the 677 yellow cameleon-Nano biosensor A single amino acid residue can determine the 692 sensitivity of SERCAs to artemisinins Erratum: A single amino acid residue can 695 determine the sensitivity of SERCAs to artemisinins Resistance of Plasmodium falciparum field isolates to 698 in-vitro artemether and point mutations of the SERCA-type PfATPase6 Plasmodium falciparum drug resistance in French Guiana: a synopsis of 702 continuous assessment from 1994 to Artemether resistance in vitro is linked to mutations in PfATP6 that also interact with mutations in PfMDR1 in travellers 706 returning with Plasmodium falciparum infections A Novel 709 SERCA Inhibitor Demonstrates Synergy with Classic SERCA Inhibitors 710 and Targets Multidrug-Resistant AML A family of cation ATPase-like molecules from Validation of the 716 hexose transporter of Plasmodium falciparum as a novel drug target Biochemical characterization and chemical inhibition of PfATP4-726 associated Na +-ATPase activity in Plasmodium falciparum 727 membranes The malaria parasite cation ATPase PfATP4 729 and its role in the mechanism of action of a new arsenal of antimalarial 730 drugs Diverse 732 antimalarials from whole-cell phenotypic screens disrupt malaria 733 parasite ion and volume homeostasis Artemisinin combination therapy fails even in the absence 735 of Plasmodium falciparum kelch13 gene polymorphism in Central India Evidence of Artemisinin-Resistant Malaria in Western 738 Triple artemisinin-based combination therapies for 741 malaria: proceed with caution Artemisinins act 743 through at least two targets in a yeast model Quick and easy yeast transformation using 746 the LiAc/SS carrier DNA/PEG method Functional studies of split Arabidopsis Ca2+/H+ 748 exchangers Table 2 : Mass spectrometry results of all proteins pulled down by DHA-biotin from both PfATP6-expressing whole yeast and PfATP6 enriched microsomes. List is separated into unassigned proteins, mitochondrial proteins, those also pulled down from P. falciparum and human cancer cells, and those also identified in the yeast microsomes.